Microbubbles combined with ultrasound therapy in ischemic stroke: A systematic review of in-vivo preclinical studies

• Published in: PloS one Vol. 13; no. 2; p. e0191788
• Main Authors: Auboire, Laurent, Sennoga, Charles A, Hyvelin, Jean-Marc, Ossant, Fréderic, Escoffre, Jean-Michel, Tranquart, François, Bouakaz, Ayache
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 08-02-2018; Public Library of Science (PLoS)
• Subjects: Acoustics; Analysis; Animals; Bioengineering; Biology and Life Sciences; Brain Ischemia - therapy; Care and treatment; Complications and side effects; Diagnosis; Disease Models, Animal; Health aspects; Imaging; Ischemia; Life Sciences; Mechanics; Medicine and Health Sciences; Methods; Microbubbles; Physics; Rabbits; Rats; Research and Analysis Methods; Stroke; Stroke - therapy; Swine; Thrombolytic Therapy - methods; Treatment Outcome; Ultrasonic Therapy - methods; Ultrasound imaging; France
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0191788

Microbubbles (MBs) combined with ultrasound sonothrombolysis (STL) appears to be an alternative therapeutic strategy for acute ischemic stroke (IS), but clinical results remain controversial.
The aim of this systematic review is to identify the parameters tested; to assess evidence on the safety and efficacy on preclinical data on STL; and to assess the validity and publication bias.
Pubmed® and Web of ScienceTM databases were systematically searched from January 1995 to April 2017 in French and English. We included studies evaluating STL on animal stroke model. This systematic review was conducted in accordance with the PRISMA guidelines. Data were extracted following a pre-defined schedule by two of the authors. The CAMARADES criteria were used for quality assessment. A narrative synthesis was conducted.
Sixteen studies met the inclusion criteria. The result showed that ultrasound parameters and types of MBs were heterogeneous among studies. Numerous positive outcomes on efficacy were found, but only four studies demonstrated superiority of STL versus recombinant tissue-type plasminogen activator on clinical criteria. Data available on safety are limited.
Quality assessment of the studies reviewed revealed a number of biases.
Further in vivo studies are needed to demonstrate a better efficacy and safety of STL compared to currently approved therapeutic options.
http://syrf.org.uk/protocols/.